Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.

Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with ...

The discovery could serve as a starting point for antiviral strategies. A research team at Ruhr University Bochum, Germany, has identified a previously unknown cellular mechanism crucial to the ...

During viral reproduction, the influenza polymerase (top left, in blue) scans along the ribonucleoprotein helix to produce messenger RNA. Credit: Science Like a camera-shy teenager, influenza’s ...

Using hypertonic saline nasal drops can reduce the length of the common cold in children by two days, according to a study that will be presented at the European Respiratory Society (ERS) Congress in ...

Recently, researchers in Dr. Chao Liu and Dr. Ping Zhang's team of Sun Yat-sen University identified a novel target of flavivirus protease NS2B3—diacylglycerol O-acyltransferase 2 (DGAT2), a key ...

Across the world, only a few dozen people appear to carry a genetic glitch that lets them brush off viruses that flatten ...